190results about "Tetrapeptides" patented technology

Compositions and methods for treating diseases associated with dysregulation of miR-21, particularly cancer, are disclosed.

The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts antithrombotic effects. The antibody of the present invention has suitable antithrombotic properties, has a wide effective therapeutic concentration window, but does not increase the risk of bleeding; it can realize the demand for moderate antithrombotic properties in clinical applications and effectively avoid bleeding problems caused by excessive effects. The present invention also discloses a method for screening drugs that target the FIXa-FVIIIa binding site.

The present disclosure relates to the technical field of polypeptides. Disclosed are a cyclic peptide, and a composition and the use thereof. The cyclic peptide of the present disclosure has a structure as shown in formula (I): Cyclo-[Gly-His-Lys-Lys] (I). The present disclosure specifically relates to the cyclic peptide or a salt thereof, or a composition thereof, and the use thereof in the preparation of a composition for caring or treating skin or mucosa.

The invention relates to coacervate-forming polymers having defined structural formulae. The invention also relates solutions comprising the coacervate-forming polymers and methods of making solutions comprising the coacervate-forming polymers. The invention also relates to polymer coacervates, comprising the coacervate-forming polymers within the coacervates, including polymer coacervates comprising cargo compounds, and methods for making such polymer coacervates. The coacervates of the invention are capable of penetrating into cells and thereby delivering cargo compounds into cells. The invention further relates to compositions, including pharmaceutical compositions, comprising the polymer coacervates. The invention also relates to uses of the coacervate-forming polymers, including medical uses.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

The present invention relates to an antibody conjugate that is particularly suitable for targeting Trop-2 expressing cells, especially tumor cells. The antibody conjugate according to the invention has the structure (1), where AB is an antibody capable of targeting Trop-2 expressing tumors, L is a linker connecting Z to D, Z is a connecting group, and L 6 -GlcNAc(Fuc) w -(G) j -S-(L 7 ) w’ -, in which G is a monosaccharide, j is an integer ranging from 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, Fuc is fucose, w is 0 or 1, w' is 0, 1, or 2, and L 7 is -N(H)C(O)CH2-, -N(H)C(O)CF2-, or -CH2-, D is exatecan, b is 0 or 1, x is 1 or 2, and y is 1, 2, 3, or 4. The present invention further relates to methods for preparing the antibody conjugates of structure (1) and applications of the antibody conjugates of structure (1).

Compositions comprising specific tetrapeptides, for use in treating, preventing, minimizing, diminishing or reversing various signs of aging of the skin are provided. The compositions are useful in improving the firmness or elasticity of skin, smoothing of fine-lines or wrinkles, reducing skin pores and hyperpigmentation, and increasing skin thickness, radiance and / or softness.

The present invention provides biomolecular glass and its use. The biomolecular glass is obtained by volatilizing a solvent from a solution of biomolecular raw materials, the solution of biomolecular raw materials comprising biomolecular raw materials, a modifier, and a solvent. The biomolecular raw materials include natural amino acids, peptides, amino acid derivatives, peptide derivatives, or mixtures of two or more of the above. The soluble biomolecular glass of the present invention has excellent biocompatibility, high light transmittance, good mechanical strength, flexible processability, and biodegradability, and can be processed into implantable or non-implantable medical materials and / or devices, fillers and stent materials, electronic sensing materials and / or devices, temporary electronic materials and / or devices, etc., and can be decomposed by living organisms or nature, with decomposition products being non-contaminating.

To provide a method for producing a high-purity peptide compound in a high yield under a condensation condition applicable even to a highly rare non-natural amino acid by using an easily available condensing agent and additive capable of suppressing prematurecleavage and also suppressing a side reaction especially in a condensation reaction process of a solid phase synthesis method of a peptide.SOLUTION: Provided is a method for producing a peptide compound, including a step of condensing a first amino acid or peptide and a second amino acid or peptide in the presence of an additive and a condensing agent to obtain a condensate, wherein the number of moles of the additive is smaller than the number of moles of the second amino acid or peptide. By using a small amount of the additive with respect to the amino acid or peptide to be added to the N-terminus, the condensation reaction can be allowed to proceed efficiently even when an amino acid having large steric hindrance is contained, and the target peptide compound can be obtained with high yield and high purity.SELECTED DRAWING: None

Provided is a method for producing a peptide compound or a salt thereof, including a step (linking step) of linking an amino group of a first amino acid or peptide and a carboxy group of a second amino acid or peptide with an amide bond, wherein a stand-alone condensing agent and one or more additive(s) are used in the linking step, and the additive(s) are one or more selected from the group consisting of HOPO, HOAt, HOOBt, HOCt, PfpOH, Oxyma, Oxyma-B, N-HOSu, and K-Oxyma.

To provide an amphiphilic compound capable of suppressing phase separation of a phospholipid membrane and stabilizing a phospholipid structure.SOLUTION: The present invention provides an amphiphilic compound for use as a stabilizer of two or more phospholipid compounds having different phase transition temperatures, the amphiphilic compound being represented by the following general formula (1).SELECTED DRAWING: Figure 2B

The present invention provides immunoconjugates of formula (I) comprising an antibody linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The present invention also provides 8-sulfonyl-2-aminobenzazepine derivative intermediate compositions comprising reactive functional groups. Such intermediate compositions are suitable substrates for the formation of the present immunoconjugates via a linker or linking moiety. The present invention further provides methods of treating cancer using the present immunoconjugates.

This invention provides novel antibody compounds and methods for using them. [Solution] Manipulated antibody compounds and their conjugates are provided, which are useful as agents for cancer immunotherapy.

The present invention provides a conjugate of an antibody and a functional substance, said conjugate having excellent desired properties, or a salt thereof. More particularly, the present invention provides a conjugate of an antibody and a functional substance, said conjugate containing a structural unit represented by formula (1) [wherein: Ig represents an immunoglobulin unit containing two heavy chains and two light chains and bonded to LA adjacent to Ig via thiol groups in the side chains of a plurality of cysteine residues in the two heavy chains and two light chains; HG represents a hydrophilic group or a monovalent group containing a hydrophilic group; CS represents a divalent group containing a cleavable moiety; ring A represents a divalent aromatic ring group which may have a substituent (wherein the divalent aromatic ring group constitutes a π-electron conjugated system together with the aforesaid cleavable moiety); V represents an oxygen atom, a sulfur atom or an amino(NH) group; LA and LB independently represent a divalent group; D represents a functional substance; and the average number n of the aforesaid bonds per immunoglobulin unit is 1.5 or more] or a salt thereof, and substances related thereto.

Peptides and Peptide-lipid conjugates are provided in which the peptide has the general Formula (I), wherein, A1 is selected from serine, threonine, O-C1-6 alkyl serine, and O-C1-6 alkyl threonine; A2 is selected from serine, threonine, O-C1-6 alkyl serine, and O-C1-6 alkyl threonine; A3 is selected from glutamic acid, glutamine, asparagine, and aspartic acid; A4 is proline; each A5 is independently selected from a natural or modified amino acid; The peptide-lipid conjugates can be used in lipid formulations for the delivery of nucleic acids.

Provided are 3-4 residue non-natural macrocyclic oligoamides comprising species of 3 or 4 monomer residues selected from the group consisting of monomers a, b, c, d, e, f, g, h, I, j, k, l, m, n, o, p, q, r, s, t, u, and v as defined in Table 1, and methods for designing such macrocyclic oligoamides.

The present invention provides an intermediate of an antibody-drug conjugate containing SN38, in which a biologically active water-soluble group PEG is introduced into the linker and the PEG is structurally modified, and a method for preparing the same. This preparation method has a simple procedure, is low cost, and is more environmentally friendly since it does not introduce heavy metal ions during the reaction. Furthermore, the intermediate of the antibody-drug conjugate synthesized by this preparation method has higher stability and efficacy than the intermediate of the antibody-drug conjugate using SN38 as a toxin in the conventional technology.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

The present application relates to steroid compounds and conjugates thereof, in particular to the compounds and conjugates thereof, or their tautomers, mesomers, racemates, enantiomers or diastereoisomers, or mixtures thereof, or pharma- ceutically acceptable salts thereof. The present application also relates to the preparation and use of the compounds and conjugates thereof.

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.

Disclosed is an antibody-drug conjugate that binds to human oncology targets.The antibody-drug conjugate comprises an antibody or its antigen-binding fragment that is covalently linked to two anti-neoplastic drug payloads through a dual linker, where at least one of the anti-neoplastic drug payloads is a BH3 mimetic.The disclosure further relates to a method and composition for use in treating cancer by administering the antibody-drug conjugate provided herein.Also disclosed is a linker-drug conjugate that comprises at least one BH3 mimetic and a method for making it.

The present invention relates to a composition for skin re-pigmentation comprising a peptide inhibitor of MIA (melanoma-inhibiting activity) protein, at least one additional peptide, and a pharmaceutically acceptable excipient. The present invention also relates to the use of the composition for the prevention and / or treatment of vitiligo. The present invention also relates to the cosmetic use of the composition for skin re-pigmentation.

Provided is a compound comprising a structure as shown in the figure accompanying the abstract, and use thereof in radionuclide labeling or the preparation of a radionuclide labeling reagent. Also provided is a radionuclide preparation comprising the compound comprising the structure as shown in the figure accompanying the abstract.

Provided is a coating solution for forming a cell scaffold with which a cell scaffold having a large thickness can be easily formed and the proliferation of cells can be enhanced. A coating solution for forming a cell scaffold according to the present invention contains a peptide-conjugated resin having a synthetic resin moiety and a peptide moiety and an alcohol solvent, a content of the peptide-conjugated resin being 0.1 wt% or more.

The present invention relates to bifunctional molecules which contain a protein-of-interest binding moiety linked through a linker group to a cellular receptor binding moiety preferably a moiety which binds to the receptor sortilin encoded by the gene SORT 1.

The present invention relates to therapeutic agents comprising autoregulatory elements, preferably where the therapeutic agent is an antigen binding protein. Methods of treatment comprising the use of said agents are also disclosed.

An object of the present invention is to provide a fusion protein that can be easily used to purify and grow target cells, and to provide a biocompatible material such as chitin or chitosan that can be easily used as a cell culture surface. The present invention provides a fusion protein comprising a region consisting of at least one peptide capable of adhering to chitins, and a region consisting of at least one peptide or protein capable of adhering to cells.

To provide a peptide with an amino acid sequence capable of cleavage with various proteases (e.g., MMP-2, MMP-3 and MMP-9).SOLUTION: The peptide comprises an amino acid sequence represented by general formula: P2P1P1'P2', where P1 is a glycine residue (Gly), P2 and P1' are hydrophobic amino acid residues, and P2' is an alanine residue (Ala), a tryptophan residue (Trp), a valine residue (Val), an arginine residue (Arg) or a threonine residue (Thr).SELECTED DRAWING: None

Aspects of the present invention provide polar groups, linker compounds, linker drugs, and conjugates thereof. TIFF2026503087000657.tif153145